Dirk Thye, Quince Therapeutics CEO

Up­dat­ed: Quince eyes PhI­II tri­al start for rare pe­di­atric dis­ease drug-de­vice as FDA lifts clin­i­cal hold

The FDA has lift­ed a tem­po­rary clin­i­cal hold on Ery­Del’s IND for its rare dis­ease drug-de­vice prod­uct, bod­ing well for Cal­i­for­nia biotech Quince Ther­a­peu­tics, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.